You have accessJournal of UrologyProstate Cancer: Detection & Screening I1 Apr 2018PD06-05 PSA KINETICS BEFORE 40 YEARS OF AGE Cristiano Linck Pazeto, Thiago Negris Lima, Jose C. Truzzi, Nairo Sumita, José de Sá, Fernando R. Oliveira, and Sidney Glina Cristiano Linck PazetoCristiano Linck Pazeto More articles by this author , Thiago Negris LimaThiago Negris Lima More articles by this author , Jose C. TruzziJose C. Truzzi More articles by this author , Nairo SumitaNairo Sumita More articles by this author , José de SáJosé de Sá More articles by this author , Fernando R. OliveiraFernando R. Oliveira More articles by this author , and Sidney GlinaSidney Glina More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.425AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The baseline PSA dosage has been proposed as a possible marker for patients who would be at increased risk compared to the general population for developing prostate cancer. The analysis of the PSA under the age of 40 years seems to be particularly interesting because it not suffers the drawbacks related to more advanced ages. Therefore, we propose determine the mean values and the kinetics of PSA at ages below 40 years. METHODS A retrospective assay in a database of a private diagnostic medicine center was performed from 2003 to 2016. All subjects with PSA dosages under 40 years were included and those values above 4.0 ng /mL were excluded. An analysis of mean, median and percentile values was performed for each age. A PSA kinetics curve was determined too. RESULTS 92995 patients performed a PSA assay between the ages of 21-39 years. Among the age ranges of 21-25, 26-30, 31-35 and 36-39 years: 5648, 13591, 30053 and 43697 dosages were accounted respectively. The mean value ranged from 0.66 (at age 22) to 0.76 ng/mL (at age 39) and the overall mean was 0.73 ± 0.45. Most of the values remained between 0.3 and 1.0 ng/mL. As for outliners, we found 3783 individuals with a baseline PSA > 1.6 ng/mL (p95) distributed among all ages. The annual PSA variation was not significant and a plateau between 23 and 32 years can be noted. A linear regression model showed that in each year there is an increase in the PSA level at approximately 0.0055 (β = 0.0055; r2 = 0.0020; p<0,001). In the analysis of the PSA kinetics according to their percentile, there were only minimal variations among the ages regardless of the percentile evaluated. CONCLUSIONS Regarding baseline PSA, this is the study enrolling the largest number of individuals. It was demonstrated the kinetics of PSA and its correction with age in patients under 40 years. Between the ages 21-39, the PSA value varied 0.1 (growth of 0.0055/year). The annual growth appears to be therefore, a very slow and progressive phenomenon, regardless of the assessed percentile. Considering this small variation, it could be proposed collecting baseline PSA at any of these ages, without causing large distortions. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e152 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Cristiano Linck Pazeto More articles by this author Thiago Negris Lima More articles by this author Jose C. Truzzi More articles by this author Nairo Sumita More articles by this author José de Sá More articles by this author Fernando R. Oliveira More articles by this author Sidney Glina More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...